We recently reported top-line data from the pivotal phase 3 trial of cabozantinib in patients with medullary thyroid cancer (the EXAM trial). Top-line results show a 2.8-fold increase in progression-free survival (PFS) versus placebo. Cabozantinib significantly improved median PFS by 7.2 months compared with placebo. The median PFS on the cabozantinib arm was 11.2 months versus 4.0 months on the placebo arm; hazard ratio (HR) 0.28, (95% CI 0.19, 0.40), p < 0.0001. The success of this trial is a tremendous milestone on multiple fronts, and it brings us closer to achieving our vision of being a commercial biopharmaceutical company that is making a positive difference in the lives of cancer patients.